Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis - PubMed (original) (raw)
Review
. 2016 Jan 19;164(2):102-13.
doi: 10.7326/M15-1432. Epub 2015 Dec 8.
- PMID: 26642233
- DOI: 10.7326/M15-1432
Review
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis
Francesco Zaccardi et al. Ann Intern Med. 2016.
Abstract
Background: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of type 2 diabetes.
Purpose: To summarize evidence for the cardiometabolic efficacy and adverse effects of once-weekly GLP-1RAs in adults with type 2 diabetes.
Data sources: Electronic databases (PubMed, Web of Science, Cochrane Central Register of Controlled Trials, U.S. Food and Drug Administration, European Medicines Agency, ClinicalTrials.gov) and congress abstracts from inception through 26 September 2015.
Study selection: Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
Data extraction: Extraction was done in duplicate, and risk of bias was assessed. No language restriction was applied.
Data synthesis: 34 trials (21,126 participants) were included. Compared with placebo, all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose; taspoglutide, 20 mg, once-weekly exenatide, and dulaglutide, 1.5 mg, reduced body weight. Among once-weekly GLP-1RAs, the greatest differences were found between dulaglutide, 1.5 mg, and taspoglutide, 10 mg, for HbA1c (-0.4% [95% CI, -0.7% to -0.2%]), once-weekly exenatide and albiglutide for fasting plasma glucose (-0.7 mmol/L [CI, -1.1 to -0.2 mmol/L]; -12.6 mg/dL [CI, -19.8 to -3.6 mg/dL]), and taspoglutide, 20 mg, and dulaglutide, 0.75 mg, for body weight (-1.5 kg [CI, -2.2 to -0.8]). Clinically marginal or no differences were found for blood pressure, blood lipid levels, and C-reactive protein levels. Once-weekly exenatide increased heart rate compared with albiglutide and dulaglutide (1.4 to 3.2 beats/min). Among once-weekly GLP-1RAs, the risk for hypoglycemia was similar, whereas taspoglutide, 20 mg, had the greatest risk for nausea (odds ratios, 1.9 to 5.9).
Limitation: Data were unavailable for semaglutide, definitions of outcomes were heterogeneous, the last-observation-carried-forward imputation method was used in 73% of trials, and publication bias is possible.
Conclusion: Compared with other once-weekly GLP-1RAs, dulaglutide, 1.5 mg; once-weekly exenatide; and taspoglutide, 20 mg, showed a greater reduction of HbA1c, fasting plasma glucose, and body weight. Taspoglutide, 20 mg, had the highest risk for nausea; risk for hypoglycemia among once-weekly GLP-1RAs was similar.
Primary funding source: Sanofi Aventis (grant to the University of Leicester).
Comment in
- The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.
Montori VM, Rodriguez-Gutierrez R. Montori VM, et al. Ann Intern Med. 2016 Jan 19;164(2):127-8. doi: 10.7326/M15-2610. Epub 2015 Dec 8. Ann Intern Med. 2016. PMID: 26641027 No abstract available. - Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
McCarthy M. McCarthy M. BMJ. 2015 Dec 9;351:h6702. doi: 10.1136/bmj.h6702. BMJ. 2015. PMID: 26656272 No abstract available.
Similar articles
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review. - Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F. Xue X, et al. Int J Clin Pract. 2016 Aug;70(8):649-56. doi: 10.1111/ijcp.12847. Epub 2016 Jul 25. Int J Clin Pract. 2016. PMID: 27456750 Review. - Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S. Madsbad S. Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29. Diabetes Obes Metab. 2016. PMID: 26511102 Free PMC article. Review. - Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Frias JP, et al. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293770 Clinical Trial.
Cited by
- Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.
Khunti K, Zaccardi F, Amod A, Aroda VR, Aschner P, Colagiuri S, Mohan V, Chan JCN. Khunti K, et al. Diabetologia. 2024 Aug 19. doi: 10.1007/s00125-024-06254-w. Online ahead of print. Diabetologia. 2024. PMID: 39155282 - Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.
Chen B, Zou Z, Zhang X, Xiao D, Li X. Chen B, et al. Front Pharmacol. 2024 Apr 3;15:1290184. doi: 10.3389/fphar.2024.1290184. eCollection 2024. Front Pharmacol. 2024. PMID: 38633611 Free PMC article. - Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
Jiang Y, Bai HS, Liu GX, Wang SY, Yin L, Hou ZT, Zhao CY, Fan GJ. Jiang Y, et al. Front Endocrinol (Lausanne). 2024 Mar 8;15:1347684. doi: 10.3389/fendo.2024.1347684. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38524632 Free PMC article. - Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Yao H, et al. BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410. BMJ. 2024. PMID: 38286487 Free PMC article. - Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.
Xie S, Zhang M, Shi W, Xing Y, Huang Y, Fang WX, Liu SQ, Chen MY, Zhang T, Chen S, Zeng X, Wang S, Deng W, Tang Q. Xie S, et al. J Am Heart Assoc. 2022 Oct 4;11(19):e026728. doi: 10.1161/JAHA.122.026728. Epub 2022 Sep 29. J Am Heart Assoc. 2022. PMID: 36172969 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials